…
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures on Emmaus Life Sciences Inc (OTCQB: EMMA) are limited; the company is described in filings as a life sciences firm pursuing therapeutic development. Long-term growth would depend on clinical progress, regulatory approvals, and successful commercialization or licensing, which may support value creation if programs advance.
Key investment risks include early-stage clinical and regulatory execution risk, likely need for additional capital, low trading liquidity typical of an OTCQB listing, and the inherent scientific and market uncertainty of biotech development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.48M | -6.42M | -3.79M | -10.62M | -15.92M |
| Net income | -7.49M | -6.45M | -3.73M | -10.69M | -15.95M |
| Selling general administrative | 11.05M | 16.69M | 23.53M | 13.17M | 13.44M |
| Selling and marketing expenses | - | - | - | 7.49M | 5.88M |
| Gross profit | 11.60M | 15.45M | 28.25M | 15.80M | 17.30M |
| Reconciled depreciation | 0.04M | 0.02M | 0.03M | 0.05M | 0.06M |
| Ebit | - | - | - | -6.64M | -6.13M |
| Ebitda | - | - | - | -6.59M | -8.04M |
| Depreciation and amortization | - | - | - | 0.05M | -1.91M |
| Operating income | 0.23M | -1.89M | 3.54M | -6.59M | -6.13M |
| Other operating expenses | - | - | - | 24.98M | 26.74M |
| Interest expense | 7.13M | 5.49M | 7.38M | 5.01M | 3.10M |
| Tax provision | 0.01M | 0.03M | -0.06M | 0.06M | 0.03M |
| Interest income | 0.27M | 0.28M | 0.68M | 0.68M | 0.76M |
| Net interest income | -6.86M | -5.21M | -6.70M | -4.33M | -2.34M |
| Income tax expense | - | - | - | 0.06M | 0.03M |
| Total revenue | 12.45M | 16.65M | 29.60M | 18.39M | 20.61M |
| Total operating expenses | 12.22M | 18.55M | 26.06M | 22.39M | 23.43M |
| Cost of revenue | 0.86M | 1.20M | 1.34M | 2.59M | 3.31M |
| Total other income expense net | -0.85M | 0.68M | -0.63M | -4.04M | -9.79M |
| Net income from continuing ops | -7.49M | -6.45M | -3.73M | -10.62M | -15.95M |
| Net income applicable to common shares | - | - | - | - | -15.95M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 21.44M | 23.60M | 35.18M | 48.23M | 56.73M |
| Other current assets | 0.36M | 0.23M | 0.60M | 1.51M | 0.39M |
| Total liab | 85.04M | 80.08M | 82.94M | 82.32M | 78.18M |
| Total stockholder equity | -63.61M | -56.48M | -47.76M | -34.09M | -21.45M |
| Other current liab | 4.58M | 6.73M | 5.20M | 15.82M | 5.91M |
| Common stock | - | - | - | 0.05M | 0.05M |
| Capital stock | 0.07M | 0.06M | 0.06M | 0.05M | 0.05M |
| Retained earnings | -270.07M | -262.57M | -256.12M | -252.34M | -241.27M |
| Other liab | - | - | - | - | 33.17M |
| Other assets | - | - | - | - | 0.29M |
| Cash | 2.13M | 1.39M | 2.55M | 2.02M | 2.28M |
| Total current liabilities | 69.07M | 63.55M | 61.51M | 54.32M | 37.10M |
| Current deferred revenue | - | - | - | 10.00M | 6.61M |
| Net debt | 28.68M | 28.34M | 27.40M | 23.08M | 27.64M |
| Short term debt | - | - | - | 24.72M | 22.00M |
| Short long term debt | 28.53M | 27.48M | 27.72M | 23.84M | 21.26M |
| Short long term debt total | - | - | - | 25.10M | 29.91M |
| Other stockholder equity | - | - | - | 220.81M | 220.02M |
| Property plant equipment | - | - | - | - | 3.63M |
| Total current assets | 7.75M | 6.77M | 11.51M | 6.29M | 9.09M |
| Long term investments | - | - | 0.00M | 18.83M | 17.62M |
| Net tangible assets | - | - | - | - | -21.45M |
| Short term investments | - | - | - | -19.97M | - |
| Net receivables | 2.80M | 2.62M | 5.52M | 0.38M | 1.04M |
| Long term debt | 2.27M | 2.25M | 2.23M | 3.73M | 4.65M |
| Inventory | 1.55M | 1.64M | 1.71M | 2.38M | 4.39M |
| Accounts payable | 4.03M | 3.31M | 3.63M | 3.79M | 2.58M |
| Accumulated other comprehensive income | - | - | - | -2.62M | -0.26M |
| Non currrent assets other | 0.21M | 0.22M | 0.30M | 0.26M | 26.39M |
| Non current assets total | 13.69M | 16.84M | 23.67M | 41.94M | 47.64M |
| Capital lease obligations | 1.76M | 3.24M | 3.48M | 3.26M | 4.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 2.17M | 2.51M | 2.23M | -2.39M | -6.38M |
| Change to liabilities | - | - | - | 0.00M | 2.06M |
| Total cashflows from investing activities | - | - | - | - | -6.38M |
| Net borrowings | -1.43M | -1.35M | 2.48M | - | 7.41M |
| Total cash from financing activities | -1.43M | -1.35M | 2.48M | 7.23M | 7.41M |
| Change to operating activities | - | - | - | - | 0.46M |
| Net income | -7.49M | -6.45M | -3.73M | -10.62M | -15.95M |
| Change in cash | 0.74M | -1.16M | 0.53M | -0.26M | -0.21M |
| Begin period cash flow | 1.39M | 2.55M | 2.02M | 2.28M | 2.49M |
| End period cash flow | 2.13M | 1.39M | 2.55M | 2.02M | 2.28M |
| Total cash from operating activities | -0.01M | -2.29M | -1.50M | -5.07M | -1.25M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 0.04M | 0.02M | 0.03M | 0.05M | 0.06M |
| Other cashflows from investing activities | - | - | - | - | -6.30M |
| Change to inventory | -0.02M | 0.01M | 0.65M | 0.43M | 0.46M |
| Change to account receivables | -0.18M | 2.90M | -5.15M | 0.61M | -0.84M |
| Other cashflows from financing activities | - | - | - | 10.37M | 16.19M |
| Change to netincome | - | - | - | 1.48M | 10.71M |
| Capital expenditures | 0.00M | 0.01M | 0.02M | 0.03M | 0.07M |
| Change in working capital | 5.91M | 4.20M | -2.62M | 2.21M | 2.11M |
| Stock based compensation | 0.03M | 0.26M | 1.26M | 0.02M | 0.55M |
| Other non cash items | 0.56M | -0.32M | 2.57M | 3.27M | 2.31M |
| Free cash flow | -0.01M | -2.30M | -1.52M | -5.10M | -1.33M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EMMA Emmaus Life Sciences Inc |
- -% |
0.02 | - | 11.90 | 0.28 | 35.48 | 2.09 | 12.71 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
21250 Hawthorne Boulevard, Torrance, CA, United States, 90503
310 214 0065
32
| Name | Title | Year Born |
|---|---|---|
| Dr. Yutaka Niihara M.D., M.P.H, M.P.H. | Chairman & CEO | 1960 |
| Mr. Willis C. Lee M.S. | Vice Chairman & COO | 1960 |
| Mr. Yasushi Nagasaki CPA, CPA | Chief Financial Officer | 1967 |
| Mr. George Sekulich | Sr. VP of Global Commercialization & Chief Information Officer | 1966 |
| Mr. Dale E. Short J.D. | Gen. Counsel | NA |
| Dr. Charles W. Stark Pharm.D, Pharm.D. | Sr. VP of Medical Affairs, Clinical, Regulatory | 1955 |
| Mr. Kurt H. Kruger M.B.A., M.S. | Consultant | 1955 |
| Mr. S. Steven Lee | Independent Consultant | 1966 |
| Mr. Willis C. Lee M.S. | CEO & Chairman of the Board | 1960 |
| Ms. Hiroko Huynh CPA | Chief Accounting Officer | 1980 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.